ISR is developing ISR048 for the novel treatment of viral infected patients with a focus on HIV.
ISR has conducted a Phase I/IIa clinical trial with a ISR048 treatment of human immunodeficiency virus infection (HIV) with excellent effects already after one month.
The positive treatment of HIV has further been verified in preclinical studies. This new concept of treating HIV infected patients represents a major technological and scientific breakthrough within the field.
ISR048 treatment has the potential to circumvent several of the problems associated with standard anti-retroviral therapy (ART).
We are now planning to conduct a Phase IIa clinical trial in Stockholm were HIV patients on ART therapy are randomized to receive ISR048 or continue with ART alone, were HIV reservoirs will be evaluated.
In addition, we are planning to conduct a Phase IIb clinical trial in 200 naive and untreated HIV patients with ISR048. ISR is collaborating with Scandinavian Development Services AB to develop the clinical trial programs and regulatory affairs.
A second generation, tailor made, anti-HIV drug (ISR049) is in development. Based on ISR’s current technology, the new chemistry is expected to have clinical advantages over ISR048. The work required is underway and ISR has signed a collaboration agreement with Isomerase Therapeutics based in Cambridge, United Kingdom to undertake the chemistry. Further patents based on new chemistry will be developed once this stage is complete.
In addition, ISR is currently developing a second line of chemical entities were ISR050 is the lead candidate. ISR050 has immunostimulatory properties that we are currently exploring in vitro and in animal models of chronic infections such as tuberculosis.
Looking into the future ISR intends on prioritizing research into using its current technology to create new anti-HIV therapies. ISR will focus on the discovery and development of more potent molecules based on ISR’s current technology.